Predicta Biosciences and CIMA LAB Diagnostics Announce Agreement to Advance Ultrasensitive Blood-Based Diagnostics for Multiple Myeloma and Other Hematological Malignancies
· media contact
AI Briefing
- • Predicta Biosciences and CIMA LAB Diagnostics partner for blood-based diagnostics for multiple myeloma and hematological malignancies.
- • Combined service integrates CIMA LAB's flow cytometry with Predicta Biosciences' GenoPredicta assay.
- • Offering available to academic institutions and biopharma in Spain, available in paid plans.
Source Summary
CAMBRIDGE, Mass. & PAMPLONA, Spain--(BUSINESS WIRE)--Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, and CIMA LAB Diagnostics from the Clínica Universidad de Navarra, a leading European University Medical Center, today announced a partnership to offer a combined service that integrates CIMA LAB’s flow cytometry capabilities with the GenoPredictaTM assay. The offering will be available to academic institutions and biopharma across Spain and the
Advertisement